Feature | Lung Cancer | October 26, 2015

New Data May Help Physicians Better Understand Risk of Lung Cancer

Researchers confirm predictive capabilities of minimally invasive procedure that offers high accuracy for positive and negative diagnosis

University of Missouri, EBUS-TBFNA, lung cancer diagnosis

October 26, 2015 — University of Missouri researchers have developed a new scoring system for a common lung cancer diagnostic test that may help physicians better understand the risk for malignancy when evaluating patients.

Endobronchial ultrasound-guided transbronchial fine-needle aspiration, or EBUS-TBFNA, is a minimally invasive procedure often used for the initial diagnosis of many lung cancers. The test uses a thin, flexible scope that passes through the mouth and into the lungs to remove a small piece of tissue for evaluation. The test is commonly used because it can provide a rapid cancer diagnosis without the need for an invasive open procedure.

“The EBUS-TBFNA procedure is a diagnostic tool for lung cancer that yields proven results,” said Lester Layfield, M.D., professor and chair of the Department of Pathology and Anatomical Sciences at the MU School of Medicine and lead author of the study. “The test categorizes the results as ‘benign,’ ‘non-diagnostic,’ ‘atypical,’ ‘suspicious for malignancy’ or ‘malignant.’ Our goal with this study was to understand the risk of cancer associated with each category.”

Layfield’s research team evaluated information from 136 patients who received a diagnosis following the EBUS-TBFNA procedure. The same patients then had an open surgical procedure to confirm whether the tissue was cancerous or benign.

Layfield’s research team found that the EBUS-TBFNA tool provided an accurate positive diagnosis of lung cancer 84 percent of the time and an accurate negative diagnosis of lung cancer 68 percent of the time. The study also provided the research team with an estimation of malignancy risks for each category, which in the future could help doctors offer patients enhanced care and counseling, Layfield said.

The study, “Malignancy Risk Associated with the EBUS-FNA Diagnostic Categories Nondiagnostic, Benign, Atypical, Suspicious for Malignancy, and Malignant for Mediastinal Lymph Node Aspirate Specimens,” recently was published in the Journal of the American Society of Cytopathology.

For more information: www.jascyto.org

Related Content

Mirada Medical and Optellum Debut AI-Based Lung Cancer Diagnosis Solution at RSNA 2017
News | Computed Tomography (CT) | December 14, 2017
Optellum, a high-tech startup in lung cancer and machine learning, and Mirada Medical recently announced a partnership...
Integration of Smoking Cessation Within CT Lung Cancer Screenings Shows Life-Saving Results
News | Lung Cancer | October 26, 2017
A study that integrated robust smoking cessation programs into an organized low-dose computed tomography (LDCT) lung...
NIH Clinical Center Releases 100,000-Plus Chest X-ray Datasets to Scientific Community
News | Artificial Intelligence | October 10, 2017
The National Institutes of Health (NIH) Clinical Center recently released over 100,000 anonymized chest X-ray images...
CompleWare and Vida Announce Joint Marketing Agreement for Respiratory Trials
News | Lung Cancer | October 05, 2017
October 5, 2017 — CompleWare and Vida recently announced a joint marketing agreement promoting complementary respirat
Biomarker Blood Test Predicts Survival Following Localized Lung Cancer Treatment
News | Lung Cancer | September 29, 2017
A new study demonstrates that a blood test to detect cancer may predict treatment outcomes for patients with localized...
Adding Radiation to Chemotherapy May Dramatically Improve Survival for Advanced-Stage NSCLC Patients
News | Stereotactic Body Radiation Therapy (SBRT) | September 26, 2017
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC)...
Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer
News | Radiation Therapy | September 25, 2017
Long-term results of a phase III clinical trial indicate survival rates for patients receiving chemoradiation for...
Matrix Analytics Beginning Validation of Deep Learning Lung CT Tools
News | Lung Cancer | September 13, 2017
Matrix Analytics announced it will clinically validate its LungDirect deep learning and predictive analytics tools for...
20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China
Technology | Lung Cancer | August 28, 2017
20/20 GeneSystems Inc. recently released in China what is believed to be the world’s first machine learning algorithm...
The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer
News | Lung Cancer | August 02, 2017
To raise public awareness of lung cancer—the leading cancer killer of men and women—the American Lung Association's...
Overlay Init